Faruqi and Faruqui, LLP Logo
Share this page

In re Opana Antitrust Litig., No. 14-10150 (N.D. Ill.)


In the Opana case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Endo Pharmaceuticals’ Oxymorphone ER, sold under the brand name Opana ER.  The proposed class alleges that Endo and would-be generic competitor Impax Laboratories entered an illegal reverse payment agreement under which Endo paid Impax more than $100 million to delay launching a less-expensive generic version of Opana ER.

Contact Counsel

Peter Kohn
Joseph T. Lukens
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 06/04/2014

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.